The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
complement 3 glomerulopathy pipeline advancements and emerging therapies in 2024
Complement 3 Glomerulopathy (C3G) is a rare kidney disorder marked by abnormal C3 protein deposits in the glomeruli. Key companies like Q32 Bio, Novartis, and Kira Pharmaceuticals are developing therapies such as KP104 and zaltenibart, with ongoing clinical trials aimed at addressing this condition's unmet medical needs. Recent advancements include Kira's promising Phase 2 results for KP104 and Omeros Corporation's FDA designation for zaltenibart, targeting this progressive disease primarily affecting children and young adults.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.